Company Overview

Carlsmed, Inc. is a medical technology company focused on spine surgery within the broader orthopedic and medical device industry. The company develops technology-enabled solutions designed to improve surgical outcomes by enabling personalized, data-driven spine procedures. Its core offering centers on aligning surgical planning, implant design, and intraoperative execution around individual patient anatomy.

The company’s primary revenue drivers are its aprevo® personalized spine surgery platform, which combines proprietary software, artificial intelligence–driven analytics, and patient-specific implants. Carlsmed primarily serves spine surgeons, hospitals, and ambulatory surgery centers, with a value proposition centered on improving alignment accuracy and reducing revision risk. Founded in 2018, the company emerged in response to limitations in standardized spine implants and has positioned itself around personalization and outcomes-based spine care. Public trading under the symbol “CARL” could not be verified; based on available public information, Carlsmed appears to be privately held, and ticker data is inconclusive based on available public sources.

Business Operations

Carlsmed operates as a single focused business centered on its aprevo® Platform, which integrates preoperative planning software, machine-learning–based alignment analytics, and patient-matched implant manufacturing. Revenue is generated through the sale of personalized implant systems and associated planning and surgical support services, typically reimbursed through existing spine procedure frameworks.

Operations are primarily U.S.-based, with engineering, clinical, and commercial activities supporting surgeon adoption and hospital partnerships. The company controls its proprietary planning software, clinical data models, and implant design specifications, while manufacturing is supported through regulated medical device production partners. No independently verifiable public disclosures confirm major joint ventures or wholly owned subsidiaries; data inconclusive based on available public sources.

Strategic Position & Investments

Carlsmed’s strategic direction emphasizes the shift from standardized spine implants toward personalized, outcomes-driven spine surgery, supported by clinical data and analytics. Growth initiatives focus on expanding surgeon adoption, increasing procedural indications, and deepening integration of artificial intelligence into preoperative decision-making.

The company has raised multiple rounds of private capital from institutional healthcare investors to support product development, clinical validation, and commercial scaling. Carlsmed has not publicly disclosed large-scale acquisitions, and no verified portfolio subsidiaries have been identified. Its technology focus places it at the intersection of digital health, AI-enabled surgical planning, and orthopedic implants, with an emphasis on evidence-based care pathways.

Geographic Footprint

Carlsmed is headquartered in San Diego, California, a major U.S. hub for medical device innovation. Its commercial and clinical activities are concentrated in the United States, where regulatory clearance, reimbursement frameworks, and surgeon training infrastructure support adoption of its platform.

While the company has indicated interest in broader market expansion, publicly verifiable evidence of material commercial operations outside North America is limited. International presence beyond exploratory or distributor-based engagement could not be independently confirmed based on available public sources.

Leadership & Governance

Carlsmed was founded by experienced medical device executives with backgrounds in spine technology and commercialization. The leadership team emphasizes a strategy centered on clinical evidence, personalization, and alignment with value-based care models in spine surgery.

Key executives include:

• Mike Cordonnier – Founder & Chief Executive Officer
• Aaron Lallone – Chief Technology Officer
• Kevin O’Boyle – Chief Financial Officer
• Jeff Smith – Chief Commercial Officer

The leadership philosophy focuses on integrating clinical insight, engineering, and data science to address longstanding variability in spine surgery outcomes, with governance aligned toward long-term clinical and economic value creation.